Timing Is the Dose: Morning Bright Light Reaches Anhedonia in Depression
- In a single-blind, placebo-controlled RCT of 81 patients with depression, randomized to four arms – morning or evening bright light at 10,000 lx versus a 100-lx placebo, 30 minutes daily for two weeks – morning bright light improved anhedonia on the Revised Physical Anhedonia Scale (RPAS) compared with morning placebo.
- Morning bright light also produced a significant delay in the salivary melatonin peak phase versus morning placebo.
- The improvement in anhedonia tracked the shift in melatonin peak phase: the correlation reached P = 0.048, and multiple linear regression confirmed the link at P = 0.026.
- Depressive symptoms on the Hamilton Depression Rating Scale (HAMD) improved after light at either timing, while the particular benefit for anhedonia was seen with morning administration.
Anhedonia is the symptom that most reliably outlives an adequate antidepressant trial – the patient sleeps, eats and functions, yet nothing lands as rewarding. This small RCT from Anhui Medical University asked a narrow, practical question: does the time of day you deliver bright light change what it treats? The answer was yes, and the lever appears to be the circadian clock rather than mood in general.
Same lux, different clock
Eighty-one patients with depression were randomized into four groups of roughly twenty: morning bright light, morning placebo, evening bright light, evening placebo. The active arms received 10,000 lx; the placebo arms 100 lx – the same lamp, the same thirty minutes a day, the same two weeks. The primary outcome was physical anhedonia (RPAS); secondary outcomes were salivary melatonin, salivary cortisol and the HAMD.
Two results separate timing from dose. First, the morning bright-light group showed a significant improvement in anhedonia versus its placebo. Second, that same group showed a significant delay in the melatonin peak phase, and the anhedonia gain moved with the phase shift – correlation P = 0.048, confirmed on multiple linear regression at P = 0.026. Depressive symptoms on the HAMD improved after light at either time of day. In other words, bright light's general antidepressant push appeared regardless of timing, while its clearest signal for the reward system came from the morning arm.
The direction of the melatonin shift is the study's most surprising detail – morning light delaying rather than advancing the peak runs against the textbook phase-response curve, and the authors treat it as exploratory. What matters clinically is the coupling: when the clock moved, anhedonia moved with it.
Where this lands in practice
If a depressed patient's residual complaint is flat reward – no anticipation, no pleasure, "everything is grey" – a two-week course of morning 10,000-lx light for thirty minutes is a cheap, drug-free adjunct with a circadian rationale, not just a mood-lifting placebo. Timing is not cosmetic here: morning delivery is where the anhedonia and circadian signal showed up. For diffuse low mood without a dominant anhedonic core, either schedule helped, so evening light is a reasonable fallback when mornings are impractical. Two habits follow: measure anhedonia explicitly rather than folding it into a total depression score, and frame light as an adjunct that targets a specific circuit – not a substitute for pharmacotherapy.
Same lamp, same lux, same thirty minutes – given in the morning, the effect on anhedonia stands out; the circadian clock, not the mood score, seems to be the target.
Single-center, single-blind design with 81 patients split across four arms (about 20 each) limits statistical power; melatonin and cortisol were salivary proxies assessed over two weeks, the delay in melatonin phase is an exploratory finding whose direction is unexpected, and generalizability beyond the sampled Chinese population is untested.